Ms. Iris Bincovich reports

INNOCAN PHARMA ANNOUNCES CLINICAL STUDY RESULTS: EVIDENCE OF REDUCED OSTEOARTHRITIS PAIN IN DOGS AFTER LIPOSOMAL CBD INJECTION

Innocan Pharma Corp. has released the results of a clinical study regarding the pain-relieving effects and safety of the company's subcutaneous liposomal CBD (Innocan's LPT platform) for dogs with osteoarthritis. Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine." The study highlights that CBD plasma levels were detected for six weeks following a single subcutaneous dose of liposomal CBD, causing minimal side effects and effectively decreasing pain, leading to improved well-being in affected dogs.

In the study, six dogs with naturally occurring osteoarthritis, unresponsive to conventional medications, were treated with a single injection of five milligram/kilogram liposomal CBD (in addition to their routine medications). The subsequent observations spanned six weeks and included measuring CBD plasma concentrations, blood work, collar activity data, and evaluations of well-being and pain. The results were encouraging; dogs exhibited a substantial drop in pain levels and an uptick in activity.

Key findings include:

• Prolonged CBD detection in the plasma with a peak concentration of 45.2 (17.8 to 72.5) ng/mL;
• Significant decrease in pain and increase in well-being for several weeks;
• Significant increase in activity (objectively measured) by the fifth and sixth weeks;
• Minor swelling at the injection site in five out of six dogs, which resolved within a few days without any treatment.

The study underscores the effectiveness and increased bioavailability of LPT-CBD tested as part of a multimodal pain management in dogs with osteoarthritis. With the drug's plasma concentrations detectable for six weeks and high exposure in terms of AUC (area under the concentration-time curve), the research suggests that this liposomal formulation could become a useful addition to pain management strategies for improving the quality of life in dogs with osteoarthritis.

Read the full study on Frontiers in Veterinary Science on the Frontiers website.

Innocan Pharma's chief executive officer, Iris Bincovich, expressed her gratitude to the dedicated team of scientists at their Liposome technology labs in Jerusalem: "Our results, covered by one of the world's leading publications, stand as a testament to the potential of our innovative formulations and drug delivery systems. I'm profoundly proud of our team's groundbreaking work." This is an important milestone since publications in the scientific community provide guided information that impacts future drug development decisions and regulatory approval. The company's publication clearly provides positive impact on both efficacy and safety parameters of LPT-CBD.

Innocan's relationship with The Hebrew University

Innocan Pharma Ltd., a wholly owned subsidiary of the company, has entered into a worldwide exclusive research and licence agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development initiative is led by Prof. Chezy Barenholz, head of the Membrane and Liposome Research Department at The Hebrew University, which is the inventor of over 55 patent families, two of which underlie Doxil, a Food and Drug Administration-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. A patent was filed covering this technology on Oct. 7, 2019.

About Innocan Pharma Corp.

Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.

Innocan Pharma signed a worldwide exclusive licence agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled release liposome to be administered by injection. Innocan Israel plans, together with Prof. Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful records in the pharmaceutical and technology sectors in Israel and globally.